Sometimes projects don’t work the way you want or need them to the first time, and as the saying goes, if at first you don’t succeed, try, try again. The Global Good Fund, a collaboration to develop technologies for humanitarian impact between Bill Gates and global invention company Intellectual Ventures (IV), recently turned to Carbon and its CLIP technology to get the job done right when their first attempt at making an affordable, easy-to-use diagnostic device for tuberculosis (TB) proved to be too expensive.
“Technology is the closest thing to magic we have in the real world, and Global Good wields its inventive magic to change the lives of those who need it most'”the billion-plus who struggle on the bottom rungs of the economic ladder,” said Nathan Myhrvold, the Founder and CEO of Intellectual Ventures. “We're always looking for ways to bring our ideas to market faster and at lower cost. Carbon is helping us do that.”
According to the 2016 Global TB Report by the World Health Organization (WHO), 10 million people around the world contracted TB in 2015, with 41% of that number going either unreported or undiagnosed – which means untreated. Most of these people live in the developing world, and the report shows that this lack of reporting and diagnosis is a critical gap in the fight against TB. That’s why Global Good is working to develop an early TB diagnostic device for the countries that don’t have a quality healthcare infrastructure.
The goal of Global Good and IV Lab scientists was to develop an accurate diagnostic method for the disease that costs less to manufacture, is easy to use, and works more quickly than traditional diagnostic methods. The team got their idea for the new product design from lateral flow assay tests that already exist for home pregnancy tests and malaria diagnostic devices.
The design for the TB test calls for a urine sample, rather than sputum collection, to detect a TB biomarker, and contains a lateral flow strip, with detection reagents, inside a thin plastic cassette. The product development team at IV Lab traditionally uses a four phase product development cycle:
IV is no stranger to 3D printing technology, and uses an FFF method to create prototypes for its inventions, like the TB diagnostic device, before turning to short-run injection molding for the final part. But, when it came to the TB cassette, this usual prototyping approach was taking too long, and, according to Carbon, each long injection mold iteration costs around $25,000 per mold. In five months, the IV Lab team only completed a few iterations, and ran into trouble with mold failures and delays related to modifying the molds, which also cost money – not the best solution when the goal is design a product that is cost-effective.
Looking for a more efficient way to manufacture the device, the IV Lab team turned to Carbon and its DLS-powered M Series 3D printer. The company’s industrial 3D printer design and powerful software helped IV Lab get back on track right away, and it took the team less than a week to 3D print its first cassette design. IV Lab also took advantage of Carbon’s end-to-end digital manufacturing process to complete 10 product design iterations, using Carbon’s Rigid Polyurethane (RPU 70) material, in half the time its traditional approach took.
Thanks to Carbon’s flexible, on-demand manufacturing, IV Lab had no constraints for minimum order quantities of parts, decreased material waste, and no parts inventory maintenance. The team was able to use the same materials and 3D printers for all parts of its product development cycle, from iterations and functional validation to manufacturing the final part.
According to Carbon’s case study, “Traditional manufacturing requires different materials and different technologies at each stage, which results in reduced flexibility, long delays, and operational inefficiencies. Leveraging Carbon's technology, IV Lab was able to reduce end-product costs significantly while increasing the number of product design iterations by two to three times. The cost reduction is a phenomenal achievement for IV Lab given the mission to create a low-cost solution for the developing world.”